JP2018148890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018148890A5 JP2018148890A5 JP2018076758A JP2018076758A JP2018148890A5 JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5 JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018076758 A JP2018076758 A JP 2018076758A JP 2018148890 A5 JP2018148890 A5 JP 2018148890A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- polypeptide
- seq
- protein
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- 230000004568 DNA-binding Effects 0.000 claims 2
- 241000598171 Human adenovirus sp. Species 0.000 claims 2
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 claims 2
- 101710125507 Integrase/recombinase Proteins 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14191660.1 | 2014-11-04 | ||
| EP14191660 | 2014-11-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Division JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018148890A JP2018148890A (ja) | 2018-09-27 |
| JP2018148890A5 true JP2018148890A5 (enExample) | 2018-12-13 |
| JP6606571B2 JP6606571B2 (ja) | 2019-11-13 |
Family
ID=52020908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Active JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
| JP2018076758A Active JP6606571B2 (ja) | 2014-11-04 | 2018-04-12 | 治療用ｈｐｖ１６ワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523902A Active JP6325751B2 (ja) | 2014-11-04 | 2015-11-03 | 治療用ｈｐｖ１６ワクチン |
Country Status (34)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040440T2 (hu) | 2014-11-04 | 2019-03-28 | Janssen Vaccines & Prevention Bv | Terápiás HPV16-oltóanyagok |
| WO2017029360A1 (en) | 2015-08-20 | 2017-02-23 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv18 vaccines |
| WO2017192418A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| CN112574317B (zh) * | 2017-01-24 | 2023-12-05 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| CN111093698B (zh) * | 2017-09-23 | 2024-04-05 | 勃林格殷格翰动物保健有限公司 | 副粘病毒科表达系统 |
| US12391746B2 (en) | 2018-02-20 | 2025-08-19 | Emory University | HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth |
| MA52003A (fr) * | 2018-03-12 | 2021-01-20 | Sqz Biotechnologies Co | Procédés de traitement de maladies associées au hpv |
| BR112021000274A2 (pt) | 2018-07-20 | 2021-04-06 | Janssen Vaccines & Prevention B.V. | Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada |
| CN108939064B (zh) * | 2018-08-06 | 2021-12-10 | 南京颂悦生物科技有限公司 | 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗 |
| CN108992665B (zh) * | 2018-08-06 | 2021-11-19 | 南京颂悦生物科技有限公司 | 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗 |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| US20230405105A1 (en) | 2019-09-20 | 2023-12-21 | Transgene Sa | Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody |
| US20230277645A1 (en) * | 2020-04-02 | 2023-09-07 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating vulvar dysplasia |
| JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用 |
| CA3182703A1 (en) * | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| EP4251640A4 (en) * | 2020-11-24 | 2024-05-29 | Ma, Muchou, Joe | DNA VACCINE AGAINST HUMAN PAPILLOMAVIRUS AND METHOD OF USE THEREOF |
| WO2023070109A1 (en) * | 2021-10-22 | 2023-04-27 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil) |
| WO2025092908A1 (zh) * | 2023-11-01 | 2025-05-08 | 仁景(苏州)生物科技有限公司 | 治疗HPV感染相关疾病的mRNA疫苗 |
| CN120607593A (zh) * | 2024-03-06 | 2025-09-09 | 诺未生物技术(无锡)有限公司 | 治疗hpv感染相关疾病的药物 |
| CN118344491B (zh) * | 2024-05-03 | 2025-02-14 | 华中科技大学同济医学院附属同济医院 | 一种hpv16/18治疗性疫苗、制备方法和应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| PT833934E (pt) | 1995-06-15 | 2005-02-28 | Crucell Holland Bv | Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| WO1998039411A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DK1818408T3 (da) | 1999-05-17 | 2011-10-17 | Crucell Holland Bv | Rekombinant adenovirus af serotypen Ad11 |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| AU785319B2 (en) * | 1999-09-16 | 2007-01-11 | Eisai Inc. | Nucleic acids encoding polyepitope polypeptides |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| CN1549730A (zh) | 2000-10-04 | 2004-11-24 | ���������Ǵ�ѧ�й��� | 黄病毒和瘟病毒衣壳蛋白的组成和使用方法 |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| CA2446110C (en) | 2001-05-01 | 2013-06-25 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| ATE447037T1 (de) | 2002-04-25 | 2009-11-15 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| WO2005089164A2 (en) * | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| JP2007522814A (ja) | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | ウイルスの精製方法 |
| EA010863B1 (ru) | 2004-11-08 | 2008-12-30 | Хромагеникс Б.В. | Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях |
| WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
| EP1996238B1 (en) | 2006-02-28 | 2016-04-06 | Vaxart, Inc. | Chimeric Adenoviral Vectors and dsRNA as TLR3 Agonist |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| EP2390340A3 (en) * | 2007-01-30 | 2012-02-22 | Transgene SA | vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity |
| DE102008010954A1 (de) * | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
| KR101504392B1 (ko) | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터의 제조방법 |
| GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| NZ601424A (en) | 2010-02-15 | 2014-07-25 | Crucell Holland Bv | Method for the production of ad26 adenoviral vectors |
| WO2012020871A1 (ko) * | 2010-08-13 | 2012-02-16 | 주식회사 제넥신 | 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물 |
| US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
| EP2601968A1 (en) | 2011-12-06 | 2013-06-12 | Deutsches Krebsforschungszentrum | HPV derived polynucleic acids for therapy |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| SG11201701506PA (en) | 2014-09-03 | 2017-03-30 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| HUE040440T2 (hu) | 2014-11-04 | 2019-03-28 | Janssen Vaccines & Prevention Bv | Terápiás HPV16-oltóanyagok |
| WO2017029360A1 (en) | 2015-08-20 | 2017-02-23 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv18 vaccines |
| WO2017192418A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
-
2015
- 2015-11-03 HU HUE15791556A patent/HUE040440T2/hu unknown
- 2015-11-03 WO PCT/EP2015/075516 patent/WO2016071306A1/en not_active Ceased
- 2015-11-03 JP JP2017523902A patent/JP6325751B2/ja active Active
- 2015-11-03 DK DK15791556.2T patent/DK3215187T3/en active
- 2015-11-03 SI SI201530481T patent/SI3215187T1/sl unknown
- 2015-11-03 AU AU2015341926A patent/AU2015341926B2/en active Active
- 2015-11-03 HR HRP20181895TT patent/HRP20181895T1/hr unknown
- 2015-11-03 CA CA2965562A patent/CA2965562C/en active Active
- 2015-11-03 PT PT15791556T patent/PT3215187T/pt unknown
- 2015-11-03 MY MYPI2017701524A patent/MY181175A/en unknown
- 2015-11-03 LT LTEP15791556.2T patent/LT3215187T/lt unknown
- 2015-11-03 MA MA40902A patent/MA40902B1/fr unknown
- 2015-11-03 MA MA046378A patent/MA46378A/fr unknown
- 2015-11-03 SG SG11201702997YA patent/SG11201702997YA/en unknown
- 2015-11-03 MD MDE20170071T patent/MD3215187T2/ro not_active IP Right Cessation
- 2015-11-03 EP EP18182588.6A patent/EP3421046A1/en not_active Withdrawn
- 2015-11-03 EA EA201790976A patent/EA035461B1/ru not_active IP Right Cessation
- 2015-11-03 KR KR1020177014129A patent/KR20170083562A/ko not_active Abandoned
- 2015-11-03 SM SM20180602T patent/SMT201800602T1/it unknown
- 2015-11-03 MX MX2017005788A patent/MX379069B/es unknown
- 2015-11-03 NZ NZ730802A patent/NZ730802A/en not_active IP Right Cessation
- 2015-11-03 RS RS20181369A patent/RS58080B1/sr unknown
- 2015-11-03 CN CN201580060062.4A patent/CN107075521B/zh active Active
- 2015-11-03 ES ES15791556T patent/ES2697903T3/es active Active
- 2015-11-03 PL PL15791556T patent/PL3215187T3/pl unknown
- 2015-11-03 EP EP15791556.2A patent/EP3215187B1/en active Active
- 2015-11-03 BR BR112017009177-1A patent/BR112017009177A2/pt not_active Application Discontinuation
- 2015-11-04 TW TW109113009A patent/TWI731654B/zh not_active IP Right Cessation
- 2015-11-04 AR ARP150103569A patent/AR102527A1/es not_active Application Discontinuation
- 2015-11-04 US US14/932,789 patent/US9701721B2/en active Active
- 2015-11-04 TW TW104136379A patent/TWI694147B/zh not_active IP Right Cessation
-
2017
- 2017-04-25 IL IL251895A patent/IL251895B/en active IP Right Grant
- 2017-05-02 CL CL2017001089A patent/CL2017001089A1/es unknown
- 2017-05-03 ZA ZA201703055A patent/ZA201703055B/en unknown
- 2017-05-03 SA SA517381457A patent/SA517381457B1/ar unknown
- 2017-05-15 CO CONC2017/0004838A patent/CO2017004838A2/es unknown
- 2017-05-22 US US15/601,278 patent/US10071151B2/en active Active
-
2018
- 2018-04-12 JP JP2018076758A patent/JP6606571B2/ja active Active
- 2018-08-08 US US16/058,411 patent/US10555996B2/en active Active
- 2018-11-15 CY CY20181101210T patent/CY1121377T1/el unknown
- 2018-12-21 AU AU2018282463A patent/AU2018282463B2/en active Active
-
2020
- 2020-01-29 US US16/775,709 patent/US11040096B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018148890A5 (enExample) | ||
| JP2019068852A5 (enExample) | ||
| JP2015533841A5 (enExample) | ||
| CN104755622B (zh) | 用于稳健t细胞和抗体应答的pr13.5启动子 | |
| RU2462513C2 (ru) | Векторы для множественной генной экспрессии | |
| AU2009319336B2 (en) | Promoters for recombinant viral expression | |
| JP2016510989A5 (enExample) | ||
| JP2014207903A5 (enExample) | ||
| KR20090005010A (ko) | Ｈｐｖ-18-기재의 유두종바이러스 백신 | |
| US12064477B2 (en) | HPV vaccine | |
| JP2009534331A5 (enExample) | ||
| JP2014502156A5 (enExample) | ||
| KR20090005011A (ko) | Ｈｐｖ-16-기재의 유두종바이러스 백신 | |
| RU2013102035A (ru) | Полипептиды е2 папилломавируса, применяемые для вакцинации | |
| JP2019514943A5 (enExample) | ||
| KR102777995B1 (ko) | 11형 인유두종 바이러스 엘1 단백질의 돌연변이체 | |
| EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| RU2015148190A (ru) | Слитые полипептиды и вакцины | |
| JP2023528984A (ja) | コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン | |
| JP2019534242A5 (enExample) | ||
| US10894966B2 (en) | Virus-based expression vectors and uses thereof | |
| JP7224332B2 (ja) | ヒトパピローマウイルス１６型のｌ１タンパク質の変異体 | |
| JP2015524420A5 (enExample) | ||
| US11413345B2 (en) | Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV) | |
| AU2017236578B2 (en) | HCV vaccines |